Project description
New stents for a safer and more secure cardiac journey
Stents have long been a lifeline for patients with heart conditions. They are essential for restoring blood flow and preventing heart-related complications. Unfortunately, once implanted, these devices can silently malfunction, causing dire consequences like heart attacks or strokes, with symptoms appearing too late. The EU-funded NIMBLE WOMENTECHEU project aims to change the landscape of stent monitoring. The NIMBLE System is a breakthrough microwave-based medical device capable of non-invasive, continuous monitoring of implanted stents. By reading the stent’s electromagnetic signature, it provides vital insights into stent status, allowing for early intervention and personalised treatment. This shift from reactive to proactive care could save lives.
Objective
Susana Amorós is the CTO and co-founder of NIMBLE Diagnostics, a MedTech company developing a first in class microwave-based medical device for the continuos, non-invasive, non-ionizing monitoring of patients with implanted stents.
Stents are one of the most implanted devices worldwide and are used to restore the correct flow of blood or other fluids. They are especially useful to prevent heart attacks or to treat their lasting symptoms, but once implanted can become blocked or damaged, which occur in 30% of the cases. The symptoms only appear after a stent is already 90% dysfunctional, which increases the incidence
of serious complications, including strokes, heart attacks or sudden death. The standard-of-care is still symptom-driven and is based on an invasive procedure called catheter angiography, involving anesthesia, X-ray exposure and 24h hospitalization recovery. This complex procedure is not standardized for recurrent monitoring, not allowing clinicians to act upon the problem until it has already manifested.
The NIMBLE System can read the electromagnetic signature of the stent non-invasively, providing information on stent satus and malfunction that can be correlated with relevant clinical outcomes. Thus, NIMBLE enables early treatments to prevent negative outcomes and personalization of pharmacological therapy, shifting from reactive to proactive care. Our technology is currently at TRL5 with an MVP that has shown and excellent results in on-going validations. However, before we can offer our solution to cardiologists and primary care clinicians, we must complete key activities in our action plan.
WomenTechEU will help us to better understand pricing and reimbursement strategies for the NIMBLE System in European markets, gain visibility with investors and collaborators, and support and mentoring from being one of the growing numbers of female entrepreneurs. Susana expects that this program supports her in bringing NIMBLE System to the market.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- social scienceseconomics and businessbusiness and managemententrepreneurship
- medical and health sciencesclinical medicinecardiologycardiovascular diseases
- medical and health sciencesbasic medicineneurologystroke
You need to log in or register to use this function
Programme(s)
- HORIZON.3.2 - European innovation ecosystems Main Programme
Funding Scheme
HORIZON-CSA - HORIZON Coordination and Support ActionsCoordinator
08916 Badalona
Spain
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.